BeiGene reports Phase I data for pamiparib in ovarian cancer
BeiGene Ltd. (NASDAQ:BGNE) reported preliminary data from nine evaluable ovarian cancer patients in the dose-escalation portion of a Phase I trial showing that pamiparib (BGB-290) led to two confirmed partial responses plus six cases of stable disease. One patient discontinued the trial before the first radiographic assessment. The recommended Phase II dose is twice-daily 60 mg pamiparib. Data were presented at the American Association for Cancer Research meeting in Chicago.
The open-label, Chinese trial is enrolling about 85 patients with locally advanced or metastatic high-grade non-mucinous ovarian cancer, including fallopian and primary peritoneal cancer, or triple-negative breast cancer (TNBC) who had disease progression following at least one line of chemotherapy...